Evidence map›Paper›PMID 36254362›Full record

ArticleJournal of the International AIDS Society2022

Making the Case for Joint Decision-Making in Future Multipurpose Prevention Technology (MPT) Choice: Qualitative Findings on MPT Attribute Preferences from the CUPID Study (MTN-045).

Nivedita L Bhushan, Petina Musara, Miriam Hartmann, Marie C D Stoner, Shweta R Shah, Josephine Nabukeera, Ivan Rukundo, Prisca Mutero, Megan A Lewis, Jeanna Piper and 3 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nivedita L BhushanRTI International, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-3417-3263
Petina MusaraClinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
Miriam HartmannRTI International, Research Triangle Park, North Carolina, USA.
Marie C D StonerRTI International, Research Triangle Park, North Carolina, USA.
Shweta R ShahRTI International, Research Triangle Park, North Carolina, USA.
Josephine NabukeeraMakerere University - Johns Hopkins University Research Collaboration (MU-JHU), Kampala, Uganda.
Ivan RukundoMakerere University - Johns Hopkins University Research Collaboration (MU-JHU), Kampala, Uganda.
Prisca MuteroClinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe.
Megan A LewisRTI International, Research Triangle Park, North Carolina, USA.
Jeanna PiperNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Mary Kate Shapley-QuinnRTI International, Research Triangle Park, North Carolina, USA.
Juliane EtimaMakerere University - Johns Hopkins University Research Collaboration (MU-JHU), Kampala, Uganda.
Alexandra M MinnisRTI International, Research Triangle Park, North Carolina, USA.ORCID 0000-0002-2943-2005

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

introductionYoung women in sub-Saharan Africa account for two-thirds of all new HIV infections and face high rates of unintended pregnancy. Multipurpose prevention technologies (MPTs) are promising products under development that are designed to simultaneously prevent HIV and unintended pregnancy. Since MPTs will be used in the context of sexual relationships, ensuring acceptability and use requires understanding the role of male partners in MPT use decision-making.

methodsThis paper draws on qualitative data from 39 couples enrolled in the Microbicide Trials Network (MTN) 045 study, conducted in 2019-2020. Partners completed a discrete choice experiment (DCE), first separately and then jointly, to measure preferences for future MPT attributes and then completed a qualitative interview. We also draw on quantitative data from interviewer observation about who dominated the decision-making process during the joint DCE. Content analysis was used to examine (1) how couples made decisions on existing non-MPT HIV and pregnancy prevention products; (2) how couples made decisions on future ideal-MPT product during the DCE; and (3) how these decision-making processes varied by decision-making dominance (10 male, 10 female and 19 equal) and interview type (19 joint and 20 separate).

resultsExisting non-MPT product decisions focused on trust between partners and product attributes, while future ideal-MPT product decisions exclusively focused on product attributes. Across existing and future products, preferences for product attributes varied by gender. Male partners were most concerned with limiting side effects impacting sexual pleasure, female partners were most concerned with limiting side effects causing physical symptoms and both were concerned with the return to fertility. Across all dominance and interview types, couples reported making decisions together and female partners were often able to negotiate with male partners for their preferred product or set of product attributes.

conclusionsResearch activities in this study provided an opportunity for couples to openly present their product attribute preferences to their partner, learn about their partner's attribute preferences, negotiate for their ideal set of attributes and ultimately choose attributes that benefited the couple without disempowering the female partner. Future research should focus on the utility of couple-based decision-making aids or similar tools for facilitating joint MPT decision-making.

Indexed as

Anti-Infective AgentsHIV InfectionsContraceptionFemaleHumansMalePregnancyPregnancy, UnplannedSexual PartnersTechnologyAnti-Infective Agentscontraceptioncouplesdecision-makingHIVmultipurpose prevention technologiespregnancy

Identifiers

PMID36254362
PMCPMC9577116

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.